DrugPatentWatch Database Preview
Drugs in Development Information for LCB01-0371
Drug Development Status for LCB01-0371: Sponsors, patents, clinical trial progress
LCB01-0371 is an investigational drug.
There have been 8 clinical trials for LCB01-0371.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Tuberculosis, Pulmonary, Tuberculosis, and [disabled in preview]. The leading clinical trial sponsors are LegoChem Biosciences, Inc and [disabled in preview].
There are two US patents protecting this investigational drug and nineteen international patents.
Summary for LCB01-0371
| US Patents | 2 |
| International Patents | 19 |
| US Patent Applications | 2 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2016-10-01) |
| Vendors | 14 |
Recent Clinical Trials for LCB01-0371
| Title | Sponsor | Phase |
|---|---|---|
| A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace | LegoChem Biosciences, Inc | Early Phase 1 |
| A Clinical Study of LCB01-0371 | LegoChem Biosciences, Inc | Phase 2 |
| IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers | LegoChem Biosciences, Inc | Phase 1 |
Clinical Trial Summary for LCB01-0371
Top disease conditions for LCB01-0371
Top clinical trial sponsors for LCB01-0371
US Patents for LCB01-0371
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LCB01-0371 | See Pricing | Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof | Legochem Biosciences, Inc. (Deajeon, KR) | See Pricing |
| LCB01-0371 | See Pricing | Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-- (substituted methyl)oxazolidin-2-one derivatives | Legochem Biosciences, Inc. (Daejeon, KR) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LCB01-0371
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LCB01-0371 | Australia | 2009297294 | 2028-09-24 | See Pricing |
| LCB01-0371 | Brazil | PI0918964 | 2028-09-24 | See Pricing |
| LCB01-0371 | Canada | 2737299 | 2028-09-24 | See Pricing |
| LCB01-0371 | China | 102171207 | 2028-09-24 | See Pricing |
| LCB01-0371 | European Patent Office | 2331529 | 2028-09-24 | See Pricing |
| LCB01-0371 | Spain | 2526120 | 2028-09-24 | See Pricing |
| LCB01-0371 | Japan | 2012503599 | 2028-09-24 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
